

5       METHOD OF MAKING SILICONE PRESSURE SENSITIVE ADHESIVES FOR DELIVERING  
          HYDROPHILIC DRUGS USING A SILICONE POLYETHER

10       [0001] This invention relates to methods of making hydrophobic matrices containing  
silicone pressure sensitive adhesives and solid powdered hydrophilic drugs and/or solid  
powdered hydrophilic excipients. More particularly, the improvement according to the  
invention resides in pre-forming a semi-solid composition containing the solid powdered  
hydrophilic drug and/or the solid powdered hydrophilic excipient, and a silicone polyether.  
The pre-formed semi-solid composition is then added to a silicone pressure sensitive adhesive  
or to a solution containing a solvent and a silicone pressure sensitive adhesive.

15       [0002] Silicone adhesive compositions can be pressure sensitive adhesives or permanent  
bonding type adhesives. Permanent bonding implies that the adhesive will actually cement  
two surfaces together, i.e., it behaves like a glue. Pressure sensitive, on the other hand, means  
that the adhesive can be stripped from a surface and re-adhered to a surface, i.e., it has the  
nature of the adhesive present on SCOTCH® brand tapes. While the focus of this invention is  
20       the pressure sensitive type of adhesive, the same components used herein can be used to  
create permanent bonding type adhesives with such components, if desired. Thus, in order to  
prepare an adhesive which will provide a permanent bond, it is required that a suitable  
crosslinking agent such as a hydrogen bearing silicone polymer and a catalyst be included  
along with the components of the pressure sensitive adhesive.

25       [0003] Typically, a silicone pressure sensitive adhesive comprises (i) a silicone resin  
containing monofunctional (M) units  $R_3SiO_{1/2}$  and tetrafunctional (Q) units  $SiO_4$ , i.e., an  
MQ silicone resin, wherein R is a hydrocarbon group, optionally a hydrocarbon group having  
1-20 carbon atoms such as methyl, ethyl, propyl, hexenyl, phenyl and the like; and (ii) a  
polydiorganosiloxane fluid or gum, optionally a high molecular weight hydroxyl endblocked  
30       polydiorganosiloxane fluid with a viscosity of 100 to 1,000,000, alternatively 5,000 to  
1,000,000 centistokes ( $mm^2/s$ ) or a high molecular weight hydroxyl endblocked  
polydiorganosiloxane gum where viscosity is expressed in terms of plasticity. Other  
ingredients known for use in silicone pressure sensitive adhesives can also be incorporated.

35       [0004] Silicone pressure sensitive adhesives can be prepared by simply mixing components  
(i), (ii) and any other optional pressure sensitive adhesive ingredients. Generally, this takes  
place in the presence of a mutual solvent such as an organic, aromatic, hydrocarbon or silicone

5 solvent, i.e., ethyl acetate, heptane, xylene, or toluene. However, the solvent can be omitted. As soon as the components are mixed, the composition is ready for use as a pressure sensitive adhesive without further treatment. It can simply be applied to the surfaces to be adhered by any suitable means, and then the surfaces are brought together. Typically, if the composition contains a solvent, the solvent is allowed to evaporate before adhering the two surfaces. The  
10 coating can be cured for a short time by heating it briefly, although curing is not generally required. Likewise, a catalyst can be added to assist in the curing, although a catalyst is not generally required.

[0005] While the focus of this invention is primarily directed to silicone pressure sensitive adhesives of the type described in US Patent 4,655,767 (April 7, 1987), the '767 patent, which  
15 is considered incorporated herein by reference, other types of silicone pressure sensitive adhesives can be used, if desired. Thus, other types of silicone pressure sensitive adhesives which can be used are described, for example, in US Patent 2,736,721 (February 28, 1956); US Patent 2,814,601 (November 26, 1957); US Patent 2,857,356 (October 21, 1958); US Patent 4,584,355 (April 22, 1986); US Patent 4,585,836 (April 29, 1986); US Patent  
20 4,591,622 (May 27, 1986); and US Patent 5,482,988 (January 9, 1996), the '988 patent; all of which are considered incorporated herein by reference. In addition, other types of adhesives having a more suitable surface pressure sensitive adhesion property can be used, such as the so-called *Soft Skin Adhesive*, i.e., the siloxane gel compositions described in detail in US Patent 5,145,933 (September 8, 1992), which are prepared from (A) alkenyl-containing  
25 polydiorganosiloxanes, (B) hydrosilicon compounds having at least three SiH groups, (C) SiH end-blocked polydiorganosiloxanes, and a (D) catalyst.

[0006] None of these references, however, either describe or suggest the method of making silicone pressure sensitive adhesive compositions according to this invention. In addition, and with particular regard to the '988 patent, the compositions prepared according to the method  
30 described in the present invention exhibit a greater resistance to deformation than the compositions in the '988 patent which possess a much lower resistance to deformation. Furthermore, while it's possible in some instances, to use the waxy type silicone polyethers of the '988 patent, in the method according to this invention, the benefits derived and attributed to the method of the present invention would be compromised.

35 [0007] It is known that hydrophilic drugs and/or hydrophilic excipients are not soluble in hydrophobic matrices of silicone pressure sensitive adhesives. It is also known that the

5 addition of hydrophilic materials to silicone pressure sensitive adhesives, generally results in the formation of large crystals and/or agglomerates, and that the crystals and agglomerates cannot be evenly distributed in the matrices of silicone pressure sensitive adhesives. This results in products containing low levels of drug and/or excipient, or products containing varying and inconsistent quantities of drugs and/or excipients.

10 [0008] However, and in accordance with the present invention, by preparing a slurry of the hydrophilic drug and/or excipient in a silicone polyether, and then adding the pre-prepared slurry of the hydrophilic drug and/or hydrophilic excipient to a silicone pressure sensitive adhesive or to a solvated silicone pressure sensitive adhesive, the hydrophilic drug and/or the hydrophilic excipient become stable in their soluble form, or are present in the hydrophobic  
15 matrix of the silicone pressure sensitive adhesive in very small discrete particles.

[0009] Among the benefits achieved according to this invention are products containing the silicone pressure sensitive adhesive and the hydrophilic drugs and/or hydrophilic excipients possess improved physical stability and an improved rate of drug release. The presence of the silicone polyether also results in additional tack-adhesion properties which increase wear  
20 properties of transdermal patches containing the hydrophobic silicone pressure sensitive adhesive matrix. Cohesiveness of the silicone pressure sensitive adhesive is not compromised, and the silicone polyether enables skilled artisans to successfully include hydrophilic materials into the hydrophobic matrices of silicone pressure sensitive adhesives.

[0010] In particular, the present invention is directed to a method of making a hydrophobic  
25 adhesive matrix, for example one containing a silicone pressure sensitive adhesive, and a solid powdered hydrophilic drug or a solid powdered hydrophilic excipient. The steps of the method consist of (i) the formation of a semi-solid composition, i.e., slurry, containing a solid powdered hydrophilic drug or a solid powdered hydrophilic excipient, and a silicone polyether. In the second step, a silicone pressure sensitive adhesive or a solution containing a  
30 solvent and a silicone pressure sensitive adhesive are combined with the semi-solid composition. The semi-solid composition and the silicone pressure sensitive adhesive or the solution containing the solvent and the silicone pressure sensitive adhesive are mixed together to form a hydrophobic matrix. The hydrophobic matrix can then be applied to a substrate, typically human skin by means of a transdermal patch for the continuous and  
35 controlled transdermal administration of drugs.

- 5 [0011] Generally, the ratio of the solid powdered hydrophilic drug and/or the solid powdered hydrophilic excipient to the silicone polyether in the semi-solid composition is not critical. It can, for example, be in a ratio of 1:100 to 100:1, alternatively 1:10 to 10:1, and alternatively 1:1 weight ratio. When a solution of silicone pressure sensitive in a solvent is used, it typically contains 10-90 percent by weight of the silicone pressure sensitive adhesive and 10-90 percent by weight of the solvent, alternatively 30-80 percent by weight of the silicone pressure sensitive adhesive and 20-70 percent by weight of the solvent.
- 10 [0012] These and other features of the invention will become apparent from a consideration of the detailed description.

15 DESCRIPTION

- [0013] The term *drug* as used herein is intended to mean substances defined as drugs under the Federal Food, Drug, and Cosmetic Act, Pub. L. No. 75-717, 52 STAT. 1040 (1938), 21 USC Sec. 201. [321]. Generally, drugs according to Sec. 201 [321] (g)(1) (B) and (C) are substances intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals; and substances, other than food, intended to affect the structure or any function of the of the body of man or other animal.
- 20 [0014] Some representative examples of such substances are (i) drugs that act upon the central nervous system such as clozapine, risperidone, chlordiazepoxide, buspirone, desipramine, maprotiline, amitriptyline, timolol, selegiline, naloxone and nalbuphine; (ii) drugs affecting renal and cardiovascular function such as acetazolamide, isosorbide, furosemide, chlorothiazide, amiloride, captopril, enalapril, lisinopril, isosorbide nitrate, nifedipine, verapamil, phenytoin, lidocaine, propranolol, amiodarone, pravastatin, probucol and ciprofibrate; (iii) drugs affecting gastrointestinal function such as cimetidine, omeprazole and ranitidine; (iv) drugs for the treatment of helminthiasis such as thiabendazole and mebendazole; (v) drugs for the treatment of microbial diseases such as trimethoprim, norfloxacin, ciprofloxacin, penicillin G nafcillin, cephalothin cefazolin, kanamycin A, neomycin, doxycycline minocycline, clarithromycin, clindamycin, flucytosine, ketoconazole, fluconazole, acyclovir and ganciclovir; (vi) drugs for the treatment of neoplastic diseases such as dacarbazine, busulfan, and triazenes; (vii) drugs for the treatment of nutrient deficiency such as folic acid, niacinamide, ascorbic acid and thiamine; (viii) drugs for hormonal replacement therapy such as estradiol, ethinyl estradiol and norethindrone; (ix)
- 30
- 35

- 5 drugs that inhibit the synthesis and actions of adrenocortical hormones such as cortisol, cortisone and prednisone; and (x) drugs used in dermatology for the treatment of dermatoses such as betamethasone dipropionate, hydrocortisone, dexamethasone sodium phosphate, retinal, tretinoin, isotretinoin, dapsone, calipotriene, ketoconazole, clotrimazole, itraconazole and arotinoid.
- 10 [0015] The term *excipients* as used herein is intended to mean substances as defined in the *Handbook of Pharmaceutical Excipients*, Ray. C. Rowe, Paul J. Weller, and Arthur H. Kibbe, (Editors), as additives used to convert pharmacologically active compounds into pharmaceutical dosage forms suitable for the administration to patients. Some representative examples of such additives are (i) sugars and sugar derivatives such as acacia, dextrin,
- 15 dextrose, fructose, lactose, maltodextrin, mannitol, sorbitol, sucrose, and xylitol; (ii) starch derivatives; (iii) cellulosic materials such as sodium carboxymethylcellulose, microcrystalline cellulose, cellulose acetate phthalate, sodium croscarmellose, methyl cellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, and hydroxypropylmethylcellulose phthalate; (iv)
- 20 polysaccharides such as dextrans, guar gum, and xanthan gum; (v) polyethers such as poloxamer and polyoxyethylene alkyl ethers; (vi) polyvinyl alcohols; (vii) acrylic and methacrylic acid polymers such as Carbopol, Carbomer, polacrilin potassium, and polymethacrylates; (viii) pyrrolidone derivatives such as povidone and crospovidone; (ix) glycuronam polymers and derivatives such as alginic acid and the calcium and sodium
- 25 alginate salts thereof; (x) solid diluents such as the calcium and magnesium salts of carbonates, calcium phosphate derivatives, calcium sulfate, magnesium oxide, potassium chloride, and potassium citrate; (xi) solid lubricants such as calcium and magnesium stearate derivatives, talc, and zinc oxide; (xii) suspending agents such as kaolin, magnesium aluminum silicate, carbon, and cyclodextrins; and (xiii) others excipient substances such as
- 30 cholesterol, fumaric acid, lecithin, gelatin, malic acid, sodium bicarbonate, sodium citrate salts, sodium stearyl fumarate, titanium dioxide, and zinc oxide.
- [0016] While nearly any silicone polyether can be used, the silicone polyethers are preferably copolymeric silicone polyethers containing dimethylsiloxo units and oxyalkylene units in their molecule. These materials often have a degree of polymerization (DP) generally
- 35 less than about twenty. Such silicone polyethers are well known in the art, commercially available, and described in detail in detail in US Patent 3,402,192 (September 17, 1968), and

5 more recently in, for example, US Patent 6,121,373 (September 19, 2000). If desired, other types of silicone polyethers can be used, but it may result in failure to obtain all of benefits of the invention.

[0017] Thus, some representative examples of other types of silicone polyethers which may be considered can be found described in detail in the following Patents, (i) crosslinked  
10 silicone polyethers in US Patent 5,136,068 (August 4, 1992); (ii) waxy silicone polyethers in US 5,482,988 (January 9, 1996); (iii) oligomeric silicone polyethers in US Patent 5,488,124 (January 30, 1996); (iv) short chain low molecular weight silicone polyethers and cyclic silicone polyethers in US Patent 5,623,017 (April 22, 1997); (v) oxyalkylene functional silanes in US Patent 5,707,550 (January 13, 1998); (vi) elastomeric silicone polyethers in US  
15 Patent 5,811,487 (September 22, 1998); and (vii) silicone polyethers containing arylalkyl groups in US Patent 6,133,370 (October 17, 2000); all of which are considered incorporated herein by reference thereto.

[0018] In the context of the present invention, the term *slurry* is intended to mean a semi-solid composition containing a solid powdered drug and/or a solid powdered excipient, and a  
20 silicone polyether. The components of the semi-solid composition are generally present in a weight ratio of 1:100 to 100:1, alternatively 1:10 to 10:1, and alternatively 1:1, i.e., one part of the silicone polyether and one part of the drug, excipient, or drug and excipient.

[0019] The pressure sensitive adhesives used in the invention are described above. Some mutual and compatible solvents for the pressure sensitive adhesives which can be used in the  
25 method according to the invention include organic, aromatic and hydrocarbon solvents such as ethyl acetate, heptane, benzene, xylene, or toluene. Silicone fluids can also be used as solvent including low molecular weight short chain linear siloxanes such as hexamethyldisiloxane, octamethyltrisiloxane, and decamethyltetrasiloxane, and cyclic siloxanes such as octamethylcyclotetrasiloxane (D<sub>4</sub>) and decamethylcyclopentasiloxane (D<sub>5</sub>).

30 These compositions can be used in the dilution/solvation of silicone pressure sensitive adhesives. The use of a solvent is optional, however, and a solvent can be omitted in those instances where solventless silicone pressure sensitive adhesives are desired. This is common practice, for example, in the customization of solventless silicone pressure sensitive adhesives having adjustable tack.

35 [0020] The method of the present invention consists of first making a slurry, i.e., a semi-solid composition, of the solid powdered hydrophilic drug and/or the solid powdered

5 hydrophilic excipient, and a silicone polyether. This slurring process allows any agglomerations of the solid powdered hydrophilic drugs to be broken up into solutions/finely dispersed particles, which in turn prevents their random and uncontrolled crystallization. It also facilitates incorporation of such materials into other liquid silicones, i.e., liquids into liquids by matching liquid viscosity. Typically, the slurring process provides a lower shear  
10 system, and therefore the drug stability is not significantly affected. Additionally, the use of silicone polyethers as the surfactant enables their participation in the release kinetics of the blend. Thus, it is known that hydrophilic materials such as silicone polyethers can function to increase release kinetic profiles by (i) homogeneously dispersing the hydrophilic phase, i.e., the excipient phase, and by (ii) stabilizing hydrophilic phases into hydrophobic silicone  
15 containing phases, with the result that the hydrophilic behavior or property of the blend is increased.

[0021] In the second step, the pre-formed semi-solid composition is mixed with a silicone pressure sensitive adhesive or a solution containing a solvent and the silicone pressure sensitive adhesive to form the hydrophobic matrix. As noted before, the process of this  
20 invention will function with nearly any adhesive matrix, alternatively any hydrophobic adhesive matrix.

[0022] The hydrophobic matrix can be applied to suitable backing materials or substrates by any conventional means such as roller coating, dip coating, extrusion, knife coating, or spray coating. No special equipment is needed to carry out the method, and simple laboratory  
25 mortars and pestles can be employed, as well as air-driven or electric general purpose mixers.

#### EXAMPLES

[0023] The following examples are set forth in order to illustrate the invention in more detail.

30 [0024] The silicone polyether used in these examples was a copolymeric silicone polyether containing dimethylsiloxo units and oxyalkylene units. It had a degree of polymerization (DP) of about fifteen, and its structure generally corresponded to the structure of the silicone polyether of Formula (I) in US Patent 6,121,373 (September 19, 2000), wherein the sum of x and y were 15.

35 [0025] The silicone pressure sensitive adhesive used in the examples was composed of (i) an MQ resin, and (ii) a hydroxyl endblocked polydiorganosiloxane fluid having a degree of

- 5 polymerization (DP), i.e., the number of repeat units, of about 1,000. It was a composition generally of the type described in US Patent 4,655,767 (April 7, 1987).



5 *EXAMPLE 1 - Ascorbyl Phosphate*

[0026] Following the mixing procedure detailed above in the specification, three compositions were prepared, and the contents and amounts of the ingredients used to form the compositions are shown in Table 1. In this example, the compositions contained varying amounts of the silicone pressure sensitive adhesive (PSA), the drug sodium ascorbyl phosphate (SAP), and the silicone polyether (SPE).

*Table 1 - Silicone Pressure Sensitive Adhesive/Drug/Silicone Polyether (percent by weight)*

COMPOSITION	PSA	SAP	SPE	Observations
1	97	3	0	Poor dispersion and large agglomerates
2	94	3	3	Uniform slurry, fine dispersion, good tack and adhesion
3	91	3	6	Uniform slurry, fine dispersion, good tack and adhesion

[0027] In Table 1, Compositions 2 and 3 which are according to the invention, provided better dispersion properties than Composition 1 which was formulated without a silicone polyether.

*EXAMPLE 2 - Niacinamide*

[0028] Example 1 was repeated and four more compositions were prepared containing a different drug. The contents and amounts of the ingredients used to form the compositions are shown in Table 2. In this example, the compositions contained varying amounts of the silicone pressure sensitive adhesive (PSA), the drug niacinamide (NIAC), and the silicone polyether (SPE).

*Table 2 - Silicone Pressure Sensitive Adhesive/Drug/Silicone Polyether (percent by weight)*

COMPOSITION	PSA	NIAC	SPE	Observations
4	85	15	0	Poor dispersion and large agglomerates
5	90	5	5	Good dispersion and no agglomerates
6	80	10	10	Good dispersion and no agglomerates
7	70	15	15	Good dispersion and no agglomerates

5

[0029] In Table 2, Compositions 4-7 provided drug release rates of 46.5 percent, 64.9 percent, 51.4 percent, and 45.7 percent, respectively. This shows that Compositions 5 - 7, which are according to the present invention, each achieved significantly improved performance than Composition 4, which was formulated without a silicone polyether. Also, 10 Compositions 5-7, which are according to the invention, provided better dispersion properties than Composition 4, which was formulated without a silicone polyether.

### EXAMPLE 3

[0030] Niacinamide and ketoconazole, the silicone polyether surfactant, and a solid 15 excipient, were added to a solvated silicone pressure sensitive adhesive. The silicone polyether and the silicone pressure sensitive adhesive were the same compositions used in the previous examples. Laminates were prepared by using a table coater and some shims. The laminates were allowed to desolvate at ambient conditions. The laminates contained 90-100 percent by weight of the silicone pressure sensitive adhesive (PSA), 5 percent by weight of a 20 silicone component which was either the silicone polyether (SPE) or a polydimethylsiloxane (PDMS) fluid having a viscosity of 10 centistoke ( $\text{mm}^2/\text{sec}$ ) used for comparison, and 5 percent by weight of the drugs Niacinamide or ketoconazole, based on the weight of the silicone matrix.

[0031] The drug dissolution was performed by means of Franz static diffusion cells. The 25 drug analysis was performed by UV analysis. The physical properties of these compositions were evaluated by electron microscopy and dynamic rheological testing. The rheological testing protocol and the dynamic rheological testing equipment used herein are well known in the art, described in detail in the '767 patent, and reference may be had thereto. Thus, the rheological complex viscosity ( $\text{Eta}^*$ ), the elastic modulus ( $G'$ ), and the viscous modulus ( $G''$ ) 30 properties, were all evaluated and determined. It should be noted that dynamic rheological testing is a useful tool for evaluating the physicochemical properties of silicone matrices over time.

[0032] The rheological results according to this example are shown in Table 3. In the Table, values such as  $3.0 \text{ E}+06$  mean  $3.0 \times 10^6$ . Table 3 indicates that there is a strong interaction of 35 the drug and the silicone polyether in the silicone matrix. These materials, when added to the silicone pressure sensitive adhesive, increase the  $\text{Eta}^*$  (complex viscosity) and the  $G'$  (elastic

5 modulus), which is beneficial. For example, the elastic modulus  $G'$  is a factor used in rheological profiles for calculating cross linking density. Another contributing factor to the high rheological values for these formulations is the presence in the silicone polyether of a hydrophobic moiety which is partitioned in the hydrophobic silicone matrix. Generally, therefore, the presence of the silicone polyether in the silicone matrix increases the

10 cohesiveness of the matrix. This is beneficial as it permits drug formulators to add additional and other types of excipients such as permeation enhancers and drug release modulators, which excipients are known to decrease rheological properties and even contribute to cold flow resulting in oozing of adhesives.

15 *Table 3 - Silicone Matrix Containing Silicone Pressure Sensitive Adhesive, Silicone Polyether or Polydimethylsiloxane Fluid, and Drug (Percent by Weight).*

Matrix	PSA	Drug	Silicone	Rheology Values @ 0.01 rad./sec.		
				Eta*(P)	G' (dyne/cm <sup>2</sup> )	G'' (dyne/cm <sup>2</sup> )
1	100 %	0	0	3.0 E+06	1.0 E+04	2.5 E+04
2	95 %	5 % Niacinamide	0	8.5 E+07	4.4 E+05	7.3 E+05
3	90 %	5 % Niacinamide	SPE	7.4 E+08	5.0 E+06	4.9 E+06
4	95 %	5 % Ketoconazole	0	7.0 E+06	4.2 E+04	5.6 E+04
5	90 %	5 % Ketoconazole	SPE	1.2 E+09	8.8 E+06	8.2 E+06
6	90 %	5 % Ketoconazole	PDMS	2.0 E+06	1.1 E+04	1.7 E+04
7	90 %	5 % Niacinamide	PDMS	1.6 E+07	9.0 E+04	1.3 E+05
8	90 %	5 % Ketoconazole	SPE	6.5 E+08	4.3 E+06	4.9 E+06
9	90 %	5 % Niacinamide	SPE	2.9 E+08	1.8 E+06	2.3 E+06

[0033] These examples also demonstrate that the presence and use of a silicone polyether as a component of the silicone matrix provides several formulating advantages. Thus, (i) the

20 silicone polyether functions as a carrier for incorporating solid drugs in a silicone matrix, (ii) acts as a crystal retardant for the drug and the excipient, and (iii) provides good in vitro flux rates and delivery profiles. As a processing aid, it enables the content uniformity compliance. Lastly, it is multi-functional to the extent that it compatibilizes solid drugs and hydrophilic

- 5    excipient solids in the silicone matrix, thereby allowing the use of a hydrophobic silicone pressure sensitive adhesive for making transdermal patches containing hydrophilic solid drugs.

[0034] Other variations may be made in compounds, compositions, and methods described herein without departing from the essential features of the invention. The embodiments of the  
10    invention specifically illustrated herein are exemplary only and not intended as limitations on their scope except as defined in the appended claims.